Widecells Share Price (WDC)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Widecells Group	LSE:WDC	London	Ordinary Share	GB00BD060S65	ORD GBP0.0025

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	+0.04p	+13.33%	0.34p	82,730,889	16:28:24

Bid Price		Offer Price	High Price	Low Price	Open Price
0.33p		0.35p	0.37p	0.30p	0.30p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Health Care Equipment & Services	0.05	-2.81	-5.00		2.7

Related Shares
Smith & Nephew (SN.), NMC Health (NMC), Salvarx Grp (SALV), Physiomics (PYC)

Widecells (WDC) Latest News (1)

Widecells News

Date	Time	Source	Headline
23/4/2019	11:30	UKREG	WideCells Group PLC Holding(s) in Company
17/4/2019	10:05	UKREG	WideCells Group PLC Holding(s) in Company
17/4/2019	10:00	UKREG	WideCells Group PLC Holding(s) in Company
16/4/2019	12:45	UKREG	WideCells Group PLC Holding(s) in Company
12/4/2019	11:35	UKREG	WideCells Group PLC Director's Interest
12/4/2019	11:30	UKREG	WideCells Group PLC Holding(s) in Company
08/4/2019	10:10	UKREG	WideCells Group PLC Holding(s) in Company
05/4/2019	12:15	UKREG	WideCells Group PLC Holding(s) in Company
05/4/2019	12:10	UKREG	WideCells Group PLC Holding(s) in Company
03/4/2019	17:37	UKREG	WideCells Group PLC Holding(s) in Company

More Widecells News

Widecells Takeover Rumours

Widecells (WDC) Share Charts

1 Year Widecells Chart

1 Month Widecells Chart

Intraday Widecells Chart

Widecells (WDC) Discussions and Chat

Widecells Forums and Chat

Date	Time	Title	Posts
23/4/2019	21:20	WideCells Group	10,281
23/4/2019	21:01	Widecells (WDC) - Iconic Labs PLC - Cellplan Excel	203
23/4/2019	21:01	Widecells (WDC) - Iconic Labs PLC	51
15/4/2019	07:51	INTERVIEW: Widecells Group PLC	2
15/4/2019	07:39	Revenue growth	2

Add a New Thread

Widecells (WDC) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2019-04-23 15:28:17	0.34	6,000,000	20,466.00	O
2019-04-23 15:24:33	0.34	2,970,588	10,100.00	O
2019-04-23 15:14:17	0.35	314,285	1,100.00	O
2019-04-23 14:55:36	0.34	3,500,000	11,725.00	O
2019-04-23 14:53:37	0.34	2,449,682	8,208.88	O

View all Widecells trades in real-time

Widecells (WDC) Top Chat Posts

Date	Subject
23/4/2019 09:20	Widecells Daily Update: Widecells Group is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker WDC. The last closing price for Widecells was 0.30p. Widecells Group has a 4 week average price of 0.26p and a 12 week average price of 0.15p. The 1 year high share price is 10.50p while the 1 year low share price is currently 0.15p. There are currently 785,552,698 shares in issue and the average daily traded volume is 57,414,719 shares. The market capitalisation of Widecells Group is £2,670,879.17. Read Full Thread Reply
02/4/2019 18:20	pwhite73: The death spiral finance is only half the problem. The other half is the lack of any positive corporate news. Unfortunately where there is death spiral funding you will often find news black outs. This is because higher share prices means the death spiral company has to compete with other share holders for trading profits. As the share price approaches 0.25p more and more traders can only sell at a loss leaving the path clear for the death spiral company to offload shares between 0.31p (closing price) - 0.26p for profit. Read Full Thread Follow Reply
02/4/2019 08:43	pwhite73: LB28 - "My point is merely it wouldn't be a bad thing anyway." Correct it would not be a bad thing for the company. Indeed it would be an excellent thing for the company. The lower the share price the more attractive it is to new investors and the more shares in the 20s the company can issue. This is why I said yesterday companies often attach their own placings to the tail of death spirals. Mug PIs can't understand why the death spiral never seems to come to an end. When the placing is done an RNS is issued advising mug PIs that the company has raised funds in the 20s in order to cancel the remainder of death spiral finance and this should help the share price. Mug PIs give three cheers not realising they've just been had. If you are holding this share all falls are bad and there are no reasons whatsoever why they would ever be good. Read Full Thread Follow Reply
02/4/2019 08:27	lb28: I am assuming the share price to recover once the fund have sold their shares. Anyway all pointless as the share price wont go into the twenties. My point is merely it wouldn't be a bad thing anyway. Read Full Thread Follow Reply
28/3/2019 18:01	electrick: Another RED day Volume has fallen off a cliff and the share price continues to slide Nothing from the company other than hints at buying businesses which are interested in selling out and cash requirements to set up infrastructure from last notes MCap currently just under £3mm so how is the company going to get a valuation over £6mm?? This is what is required to see a share price at £0.007.... I still wait for the twenties. And believe will see it before a sustainable rise ( news) Love this board. It is real playground stuff Read Full Thread Follow Reply
22/3/2019 07:56	pwhite73: 1bs It certainly does not mean the directors are confident the share price will ever get to 2.46p. You can liken it to directors who award themselves options that can only be exercised at 5 times the current share price. Mug PIs think "wow they must be really confident". The directors then go on to pay themselves high wages out of dilutions that are a fifth of the current share price. Its all to trick mug PIs into buying the shares. An AIM scam is a legitimate company that has no realistic chance of making any money and survives solely on dilution after dilution. Read Full Thread Follow Reply
21/3/2019 16:02	mcfly79: Right, from a quick look at the prospectus this is my take: Ordinary share before any new issuance: 151m Conversion shares from notes: 1,060m Warrant shares: 378m The Conversion Price for the Notes is 90% of the lowest closing volume-weighted average price of Ordinary Shares (VWAP) in the 15 trading days prior to conversion, provided that the Conversion Price will not be less than the nominal value of the Ordinary Shares (0.25p). The conversion price for the warrants is 2.46p We can assume full conversion of the notes. A fair number have already been issue at a 0.25p conversion price resulting in 575m share as the current share capital. Future conversion price should be higher so total shares after all conversion will maybe be between 800m and 1.2bn. Based on the current share price that means a c.£4m market cap. And then potential 378m more shares if the price heads above the warrant exercise price. Thoughts on cash: The company had only £1k of cash as at 31 Jan 2019 and £0.4m of debt (other than the convertible debt). Since 31 Jan the company received a £47k drawdown on 4 Feb 2018 and should have received £893k following the drawdown notice on 6th March. A further £265k is due in June and a further £200k can be called in July. Potentially three further tranches of £200k can be called thereafter. I don’t know what the cash burn of the company is but I think it is substantial (unless the new business can generate cash quickly). From the prospectus: ‘The amount of the Company’s cash shortfall under the Company’s reasonable worst case scenario as at 29 February 2020 (i.e 12 months from the date of this document) is expected to be £1.8m.’ (I believe the worst case assumed the £893k drawdown but no further drawdowns). So a company with a £4m market cap, with perhaps around £800k in cash currently. Thoughts Read Full Thread Follow Reply
16/3/2019 08:41	texas ranger: If you guys can correlate the number of shares vs/ mcap vs share price There is a strong correlation (inverse) Essentially the share price has declined substantially since issuance of shares. Meaning dilution 175% more shares in issue shows approximately about a -65% share price devaluation so far. This is in reference to 1.2p when the news came Just check out the chart. shares issue going up rapidly exponential is inversely correlated with s.p, and hence the share price will be drifting in a logarithmic decline, slow and painful new cheaper shares is coming on the market every day, meaning the ones who at 0.5p, 0.6p will have difficult to break even. Now it's anticipated that about 700m or 800m shares going to be issued, another 2-fold in number of shares. we can actually project that share price will eventually drifty towards 0.15p or less. The inverse of exponential is log. The pumping of the shares is becoming more difficult, as more money is needed for incremental rise, Clearly the amount of buys going thru, as some experts pointed out 15m more buys than sells, we can say the Luxembourg is unloading their shares. They have offloaded 60m-70m above 0.40. They had 110m to sell. Once the 40m is sold, they will convert anothef batch possibly this time 150m worth, to keep holding below 30% as the current number of shares in issue is 460 You should expect another 30% dilution this week. Taking the share price around 0.30p Then next one it will be 200m shares most likely a week later. Read Full Thread Follow Reply
14/3/2019 12:41	upsondowns: I'm with you there. They will want the share price up to make a decent wedge on any further conversions. Then if that happens in a few weeks time the conversion price will be even higher. So sort of forcing the price up.Hopefully news by then will shoot the share price to 2p at least.Then we will regret not filling our big knickers now Read Full Thread Follow Reply
08/3/2019 17:18	letmepass: : UK Regulatory (RNS & others)TIDMWDCRNS Number : 0841CWideCells Group PLC27 September 201827 September 2018WideCells Group PLC ('WideCells Group' or 'the Group')Financing AgreementWideCells Group PLC, the healthcare services company focused on providing stem cell services and insurance for stem cell treatment, announces it has obtained a flexible and staged GBP2.7 million financing agreement (the 'Agreement') with European High Growth Opportunities Securitization Fund (the 'Investor') represented by its management company, European High Growth Opportunities Manco SA.Terms of the AgreementWideCells Group has entered into an agreement with the Investor in relation to the issue by the Group (the 'Bond Issue') to the Investor (or its affiliates) of convertible bonds (the 'Bonds') with warrants attached for a principal amount of up to GBP2,700,000 (the 'Total Commitment'). Under the terms of the agreement, the Bonds will convert into ordinary shares of GBP0.0025 each in the Company ('Ordinary Shares'), and the warrants entitle ABO to subscribe for Ordinary Shares at a pre-determined price (the 'Warrants').It is expected that the Bonds will be issued and subscribed for in sequential tranches as detailed below:i. GBP635,000 to be subscribed for and paid to the Company immediately; ii. GBP1,000,000 to be subscribed for and paid to the Company immediately on the later of either (a) 15 November 2018, or (b) once a prospectus has been validated and approved by the Financial Conduct Authority (further detail on which is included below);iii. GBP265,000 to be subscribed for and paid to the Company immediately three calendar months after the second tranche if the Company elects to draw down that third tranche; andiv. four subsequent tranches each of aggregate nominal value of GBP200,000 if the Company elects to draw down those tranches.The directors of the Company have sufficient authority to issue shares and rights to subscribe for shares to issue the first tranche of the Bond Issue, but will be required to call a General Meeting to receive authority from shareholders to enable the balance of the Bond Issue, including the attached Warrants, to be implemented. Furthermore, at the current share price, the Bond Issue will result, on full conversion of the Bonds and the attached Warrants, in the issue of substantially more than 20% of the Group's issued share capital triggering a requirement to issue a prospectus (which would need to be approved by the Financial Conduct Authority) prior to the issue of the shares (the 'Prospectus Requirement').The first two drawdowns of the Bonds (totalling GBP1,635,000 in aggregate) are mandatory, but the drawdown of the remainder of the Bonds is not mandatory, although the Investor does have the right to require the Company to draw down any two of the remaining tranches. The Bonds are to be freely transferable and have a maturity of 12 months, after which all the Bonds will be mandatorily converted into Ordinary Shares to the extent not previously converted. The conversion price for the Bonds will be 90% of the lowest closing volume-weighted average price of Ordinary Shares ('VWAP') in the 15 trading days prior to conversion.In relation to the Warrants, all Warrants are exercisable for a period of five years from their date of issue and are to be freely transferable. There are to be two series of Warrants (i.e. Warrants A and Warrants B). The number of Warrants A to be issued on the drawdown of the second tranche would be equivalent to 15% of the Total Commitment divided by the exercise price of the Warrants A. The number of Warrants B to be issued on the drawdown of each tranche will be equivalent to 20% of the nominal value of the Bonds issued in such tranche divided by the exercise price of the Warrants B , although the Warrants B to be issued in respect of the first tranche will actually be issued on the drawdown of the second tranche.The exercise price of the Warrants A will be 120% of the lower of:-- the lowest closing VWAP of the 15 trading days immediately preceding the date of signing of the letter of intent signed by the Company and Alpha Blue Ocean Inc., ('ABO') on 13 September 2018 in relation to the Bond Issue (the 'LOI'); and-- the lowest closing VWAP of the 15 trading days immediately preceding the request to issue the first tranche.The exercise price of the Warrants B will be 120% of the lowest closing VWAP of the 15 trading days immediately preceding the request to issue the relevant tranche (or, in respect of the first tranche only, the lowest closing VWAP of the 15 trading days immediately preceding the date of signing of the LOI in relation to the Bond Issue, if such figure is lower).Use of proceedsProceeds from the Agreement will be used to support the roll out and growth of the Group's stem cell storage and processing (WideCells) and insurance (CellPlan) service offerings and for general working capital purposes. The Board's primary focus is on building the sales revenue of its two core stem cell service offerings by maximising current contract agreements.Within the storage and processing division (WideCells), the Group's offering is a package known as BabyCells, which comprises umbilical cord blood and umbilical cord tissue collection following the award of an HTA license and processing together with one year's storage. The Group launched this product in February 2018 and is now focussed on driving sales uptake within the UK and Europe. This strategy has been strengthened by a recent agreement with an experienced stem cell sales specialist in the UAE and Lebanon.Alongside this, the Group's innovative stem cell insurance division is focussed on increasing the roll-out of CellPlan in a selection of targeted countries in which it currently has commercial agreements in place to facilitate product uptake: namely, the UK and Spain, in both of which it is currently operational, and Brazil, Thailand, India and Singapore, where product launch is targeted to commence on a phased basis in H1 2019.WideCells' CEO, João Andrade, said, "This agreement with ABO provides WideCells Group with financial security so that we can move forward positively and centre our attention on our primary goal and responsibility of building revenues and long-term shareholder value. With a supported balance sheet, we are able to focus on the uptake and sales of our primary stem cell insurance and storage services, which we believe provide the business with strong growth prospects. We have a number of commercial agreements in place to facilitate this and are committed to delivering on our focussed sales strategy for the benefit of all stakeholders."ABO's COO, Hugo Pingray, said "ABO is very pleased to enter into this financing agreement with WideCells which fits ideally into our portfolio. We believe that the Company has the potential to revolutionise the booming stem cell industry and ultimately, to make access to potentially lifesaving treatments much more affordable. We are confident that the management will effectively leverage the funds we provide, to create value for its shareholders in further consolidating and developing its current pipeline. Read Full Thread Follow Reply
08/3/2019 07:47	jungmana: the higher the share price the lesser the dilution as the bond conversion price is based on the lowest closing day share price of the last 15 trading days; "The Conversion Price for the Notes on a Voluntary or Mandatory Conversion alike will be 90% of the lowest closing volume-weighted average price of Ordinary Shares (VWAP) in the 15 trading days prior to conversion, provided that the Conversion Price will not be less than the nominal value of the Ordinary Shares.” Read Full Thread Follow Reply

Widecells share price data is direct from the London Stock Exchange

Your Recent History

LSE

WDC

Widecells

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20190424 02:26:11